Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research And Development Expense	$ 130,521	$ 85,618	$ 43,584
General and administrative	75,543	61,291	29,159
Total operating expenses	206,064	146,909	72,743
Loss from operations	(206,064)	(146,909)	(72,743)
Investment Income, Net	17,187	4,746	4
Other expense, net	(40)	(18)	(15)
Net loss	(188,917)	(142,181)	(72,754)
Net loss attributable to redeemable convertible noncontrolling interests	0	0	(2,109)
Exchange of redeemable noncontrolling interest shares-deemed dividend	0	0	(99,994)
Net loss attributable to common stockholders/members	$ (188,917)	$ (142,181)	$ (170,639)
Net loss per share, basic	$ (2.37)	$ (2.17)	$ (4.62)
Net loss per share, diluted	$ (2.37)	$ (2.17)	$ (4.62)
Weighted-average number of common shares used in computing net loss per share, basic	79,773,004	65,466,773	36,960,569
Weighted-average number of common shares used in computing net loss per share, diluted	79,773,004	65,466,773	36,960,569